ExodusPoint Capital Management LP trimmed its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 44.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 105,668 shares of the biotechnology company's stock after selling 83,431 shares during the quarter. ExodusPoint Capital Management LP owned 0.21% of REGENXBIO worth $817,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its holdings in REGENXBIO by 273.1% in the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 2,510 shares during the period. FMR LLC boosted its stake in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock valued at $28,000 after buying an additional 1,656 shares during the period. KLP Kapitalforvaltning AS purchased a new position in REGENXBIO during the fourth quarter worth about $54,000. EntryPoint Capital LLC purchased a new position in REGENXBIO during the fourth quarter worth about $97,000. Finally, Teacher Retirement System of Texas increased its stake in REGENXBIO by 19.9% in the 4th quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company's stock worth $97,000 after acquiring an additional 2,088 shares during the last quarter. Hedge funds and other institutional investors own 88.08% of the company's stock.
REGENXBIO Stock Performance
RGNX stock traded up $0.28 during mid-day trading on Tuesday, reaching $6.61. 621,228 shares of the stock traded hands, compared to its average volume of 795,021. REGENXBIO Inc. has a one year low of $5.04 and a one year high of $18.65. The stock has a market capitalization of $331.27 million, a PE ratio of -1.31 and a beta of 1.26. The business has a 50-day moving average price of $6.95 and a two-hundred day moving average price of $8.24.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping analysts' consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The company had revenue of $21.21 million during the quarter, compared to analyst estimates of $23.70 million. On average, equities analysts expect that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of analysts have recently issued reports on the stock. Morgan Stanley lifted their price objective on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, March 14th. Raymond James started coverage on REGENXBIO in a research report on Friday, February 7th. They set an "outperform" rating and a $27.00 price objective on the stock. Leerink Partners set a $24.00 price target on shares of REGENXBIO in a research report on Tuesday, March 18th. The Goldman Sachs Group cut shares of REGENXBIO from a "buy" rating to a "neutral" rating and cut their price objective for the company from $38.00 to $14.00 in a research note on Tuesday, February 11th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $30.00 target price on shares of REGENXBIO in a research report on Tuesday, January 21st. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, REGENXBIO currently has an average rating of "Moderate Buy" and an average price target of $31.88.
Get Our Latest Stock Analysis on REGENXBIO
About REGENXBIO
(
Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Further Reading
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
